Association of the numbers of CD163+ cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma

Journal of Dermatological Science

Volumn 68, Issue 1, 2012, Pages 45-51

  Sugaya, Makoto ^a   Miyagaki, Tomomitsu ^a   Ohmatsu, Hanako ^a   Suga, Hiraku ^a   Kai, Hiromichi ^a   Kamata, Masahiro ^a   Fujita, Hideki ^a   Asano, Yoshihide ^a   Tada, Yayoi ^a   Kadono, Takafumi ^a   Okochi, Hitoshi ^b   Sato, Shinichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Atopic dermatitis; CD163; CD68; Cutaneous T cell lymphoma; Macrophages; Psoriasis

Indexed keywords

CD163 ANTIGEN; CD68 ANTIGEN; IMMUNOGLOBULIN E; INTERLEUKIN 2 RECEPTOR; STEROID; THYMUS AND ACTIVATION REGULATED CHEMOKINE;

ADULT; ANTIGEN EXPRESSION; ARTICLE; ATOPIC DERMATITIS; BLOOD LEVEL; CANCER GROWTH; CANCER INFILTRATION; CD163 ANTIGEN BLOOD LEVEL; CD163 ANTIGEN SKIN LEVEL; CELL COUNT; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN E BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; LYMPHOMA CELL; MACROPHAGE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PSORIASIS; RADIOTHERAPY; SKIN DEFECT; THYMUS AND ACTIVATION REGULATED CHEMOKINE BLOOD LEVEL; TISSUE LEVEL; ULTRAVIOLET RADIATION;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CHEMOKINE CCL17; DERMATITIS, ATOPIC; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULIN E; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHOMA, T-CELL, CUTANEOUS; MACROPHAGE ACTIVATION; MACROPHAGES; MIDDLE AGED; PHENOTYPE; PSORIASIS; RECEPTORS, CELL SURFACE; RECEPTORS, INTERLEUKIN-2; SKIN; SKIN NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84865746838     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2012.07.007     Document Type: Article

References (46)

1. Biswas S.K., Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010, 11:889-896.
2. Gordon S., Martinez F.O. Alternative activation of macrophages: mechanism and functions. Immunity 2010, 32:593-604.
3. Martinez F.O., Gordon S., Locati M., Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol 2006, 177:7303-7311.
4. Mantovani A., Sica A., Sozzani S., Allavena P., Vecchi A., Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004, 25:677-686.
5. Mosser D.M. The many faces of macrophage activation. J Leukoc Biol 2003, 73:209-212.
6. Goerdt S., Orfanos C.E. Other functions, other genes: alternative activation of antigen-presenting cells. Immunity 1999, 10:137-142.
7. Komohara Y., Hirahara J., Horikawa T., Kawamura K., Kiyota E., Sakashita N., et al. AM-3K, an anti-macrophage antibody, recognizes CD163, a molecule associated with an antiinflammatory macrophage phenotype. J Histochem Cytochem 2006, 54:763-771.
8. Martinez F.O., Gordon S., Locati M., Mantovani A. Transcriptional profiling of human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol 2006, 177:7303-7311.
9. Qian B.Z., Pollard J.W. Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141:39-51.
10. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer related inflammation. Nature 2008, 454:436-444.
11. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004, 4:71-78.
12. Flamm J., Benesch A. Tumor-associated mononuclear cell infiltrate and recurrence rate in the superficial urothelial carcinoma of the urinary bladder. Urol Int 1986, 41:187-191.
13. Davidson S.E., West C.M., Hunter R.D. Lack of association between in vitro clonogenic growth of human cervical carcinoma and tumour stage, differentiation, patient age, host cell infiltration or patient survival. Int J Cancer 1992, 50:10-14.
14. Leek R.D., Landers R.J., Harris A.L., Lewis C.E. Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer 1999, 79:991-995.
15. Shimura S., Yang G., Ebara S., Wheeler T.M., Frolov A., Thompson T.C. Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res 2000, 60:5857-5861.
16. Forssell J., Oberg A., Henriksson M.L., Stenling R., Jung A., Palmqvist R. High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res 2007, 13:1472-1479.
17. + macrophages within the immediate sprouting microenvironment. Blood 2010, 115:5053-5056.
18. Niino D., Komohara Y., Murayama T., Aoki R., Kimura Y., Hashikawa K., et al. Ratio of M2 macrophage expression is closely associated with poor prognosis for angioimmunoblastic T-cell lymphoma (AITL). Pathol Int 2010, 60:278-283.
19. Zaki M.A., Wada N., Ikeda J., Shibayama H., Hashimoto K., Yamagami T., et al. Prognostic implication of types of tumor-associated macrophages in Hodgkin lymphoma. Virchows Arch 2011, 459:361-366.
20. Wada N., Zaki M.A., Hori Y., Hashimoto K., Tsukaguchi M., Tatsumi Y., et al. Tumour-associated macrophages in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group. Histopathology 2012, 60:313-319.
21. Willemze R., Jaffe E.S., Burg G., Cerroni L., Berti E., Swerdlow S.H., et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005, 105:3768-3785.
22. Hwang S.T., Janik J.E., Jaffe E.S., Wilson W.H. Mycosis fungoides and Sézary syndrome. Lancet 2008, 371:945-957.
23. Vonderheid E.C., Bernengo M.G., Burg G., Duvic M., Heald P., Laroche L., et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 2002, 46:95-106.
24. Wu X.S., Lonsdorf A.S., Hwang S.T. Cutaneous T-cell lymphoma: roles for chemokines and chemokine receptors. J Invest Dermatol 2009, 129:1115-1119.
25. Sugaya M. Chemokines and cutaneous lymphoma. J Dermatol Sci 2010, 59:81-89.
26. Günther C., Zimmermann N., Berndt N., Grosser M., Stein A., Koch A., et al. Up-regulation of the chemokine CCL18 by macrophages is a potential immunomodulatory pathway in cutaneous T-cell lymphoma. Am J Pathol 2011, 179:1434-1442.
27. Wu X., Sells R.E., Hwang S.T. Upregulation of inflammatory cytokines and oncogenic signal pathways preceding tumor formation in a murine model of T-cell lymphoma in skin. J Invest Dermatol 2011, 131:1727-1734.
28. Holness C.L., Simmons D.L. Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins. Blood 1993, 81:1607-1613.
29. Jensen T.O., Schmidt H., Møller H.J., Høyer M., Maniecki M.B., Sjoegren P., et al. Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. J Clin Oncol 2009, 27:3330-3337.
30. Wasik M.A., Vonderheid E.C., Bigler R.D., Marti R., Lessin S.R., Polansky M., et al. Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma. Clinical and prognostic implications. Arch Dermatol 1996, 132:42-47.
31. Kakinuma T., Sugaya M., Nakamura K., Kaneko F., Wakugawa M., Matsushima K., et al. Thymus and activation-regulated chemokine (TARC) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides. J Am Acad Dermatol 2003, 48:23-30.
32. Günther C., Bello-Fernandez C., Kopp T., Kund J., Carballido-Perrig N., Hinteregger S., et al. CCL18 is expressed in atopic dermatitis and mediates skin homing of human memory T cells. J Immunol 2005, 174:1723-1728.
33. Yawalkar N., Tscharner G.G., Hunger R.E., Hassan A.S. Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis. J Dermatol Sci 2009, 54:99-105.
34. Fuentes-Duculan J., Suárez-Fariñas M., Zaba L.C., Nograles K.E., Pierson K.C., Mitsui H., et al. A subpopulation of CD163-positive macrophages is classically activated in psoriasis. J Invest Dermatol 2010, 130:2412-2422.
35. Pettersen J.S., Fuentes-Duculan J., Suárez-Fariñas M., Pierson K.C., Pitts-Kiefer A., Fan L., et al. Tumor-associated macrophages in the cutaneous SCC microenvironment are heterogeneously activated. J Invest Dermatol 2011, 131:1322-1330.
36. Miyagaki T., Sugaya M., Suga H., Ohmatsu H., Fujita H., Asano Y., et al. Increased CCL18 expression in patients with cutaneous T cell lymphoma: association with disease severity and prognosis. J Eur Acad Dermatol Venereol 2012 March 9, [Epub ahead of print]. 10.1111/j.1468-3083.2012.04495.x.
37. Lau S.K., Chu P.G., Weiss L.M. CD163: a specific marker of macrophages in paraffin-embedded tissue samples. Am J Clin Pathol 2004, 122:794-801.
38. Nguyen T.T., Schwartz E.J., West R.B., Warnke R.A., Arber D.A., Natkunam Y. Expression of CD163 (hemoglobin scavenger receptor) in normal tissues, lymphomas, carcinomas, and sarcomas is largely restricted to the monocyte/macrophage lineage. Am J Surg Pathol 2005, 29:617-624.
39. Droste A., Sorg C., Hogger P. Shedding of CD163, a novel regulatory mechanism for a member of the scavenger receptor cysteine-rich family. Biochem Biophys Res Commun 1999, 256:110-113.
40. Møller H.J., Moestrup S.K., Weis N., Wejse C., Nielsen H., Pedersen S.S., et al. Macrophage serum markers in pneumococcal bacteremia: prediction of survival by soluble CD163. Crit Care Med 2006, 34:2561-2566.
41. Aristoteli L.P., Møller H.J., Bailey B., Moestrup S.K., Kritharides L. The monocytic lineage specific soluble CD163 is a plasma marker of coronary atherosclerosis. Atherosclerosis 2006, 184:342-347.
42. Hiraoka A., Horiike N., Akbar S.M., Michitaka K., Matsuyama T., Onji M. Soluble CD163 in patients with liver diseases: very high levels of soluble CD163 in patients with fulminant hepatic failure. J Gastroenterol 2005, 40:52-56.
43. Matsushita N., Kashiwagi M., Wait R., Nagayoshi R., Nakamura M., Matsuda T., et al. Elevated levels of soluble CD163 in sera and fluids from rheumatoid arthritis patients and inhibition of the shedding of CD163 by TIMP-3. Clin Exp Immunol 2002, 130:156-161.
44. Nakayama W., Jinnin M., Makino K., Kajihara I., Makino T., Fukushima S., et al. Serum levels of soluble CD163 in patients with systemic sclerosis. Rheumatol Int 2012, 32:403-407.
45. + macrophages and local production of soluble CD163 with decreased lymphocyte activation in spondylarthropathy synovitis. Arthritis Rheum 2004, 50:1611-1623.
46. Moestrup S.K., Moller H.J. CD163: a regulated hemoglobin scavenger receptor with a role in the antiinflammatory response. Ann Med 2004, 36:347-354.